PDCD1 and non-small cell lung carcinoma: All these data suggest that, following confirmation and extension of our results in future, peripheral blood immune cell biomarkers may provide a precious and practical strategy to predict early responses to anti–PD-1 therapy in combination with chemotherapy that may assist in the treatment of patients with NSCLC.